A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours

Despite some encouraging data, systemic treatment of CNS metastases from solid tumors remains experimental. Better knowledge on the evolving epidemiology and biology of BM are key elements for the development of new treatment strategies and identification of promising therapeutic targets for new compounds. Further biological findings may help to better understand the heterogeneity between the primary tumor and the CNS metastases and to identify new targets for therapy thus improving patients' outcome. In this context, the Oncodistinct network and the Jules Bordet institute propose to build a multidisciplinary Brain Metastases Clinical Research Platform called BrainStorm. The BrainStorm program will focus on patients with newly diagnosed non-CNS metastatic solid tumors with high risk of developing CNS metastases and will allow building a large clinico pathological database for CNS metastases including ctDNA analyzes from CSF samples. Substudies will be proposed at each time-period with the final objective to develop innovative treatment approaches and strategies.

NCT Number	NCT04109131
Lead Sponsor	Jules Bordet Institute Collaborators: Fondation Cancer, Belgique, Les Amis, Bristol-Myers Squibb, Fondation Cancer, Luxembourg
Conditions	CNS Metastases
Enrollment	600 participants
Start Date	2020-07-01
Primary Completion	2028-01 (estimated)
Study Completion	2029-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-06